Public-registry site landscape for NCT07724366, a Psoriasis study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07724366 (registry record) |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
| Condition(s) | Psoriasis |
| Phase | PHASE3 |
| Listed sites | 43 |
| Site countries | China |
At Peking University Third Hospital — one of the facilities listed on this trial — 7 other studies are actively recruiting Psoriasis patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07724366 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →